Through clinical trial, the effective rate for curing hepatitis B comes up to 94.9%, the cure rate up to 59.5%, the existent drugs are incomparoble with it, in addition, it has no ang side effects to the stomach, kidney, liver and spleen. For the ordinary patient there is no need ...
A high functional cure rate was induced by pegylated interferon alpha-2b treatment in postpartum hepatitis B e antigen-negative women with chronic hepatitis B virus infection: an exploratory studydoi:10.3389/fcimb.2024.1426960HEPATITIS BHEPATITIS associated antigen...
[Conclusion] Freshman's preventive awareness against hepatitis B still needs to be reinforced; medical workers must enhance the publicity and education of hepatitis B prevention and cure for university freshman. 展开 关键词: Hepatitis B Vaccine Inoculation University Freshman Prevention ...
Rate in Late Trial Hepatitis C Drug Raises Cure Rate in Late TrialHepatitis C Drug Raises Cure Rate in Late TrialPollack, Andrew
You may or may not need treatment for chronic hepatitis B. Your doctor will likely only treat you if you have signs of liver disease because the medicines used seem to work best in these people. They don't cure it, but they boost your immune system to slow down how fast the virus rep...
You may or may not need treatment for chronic hepatitis B. Your doctor will likely only treat you if you have signs of liver disease because the medicines used seem to work best in these people. They don't cure it, but they boost your immune system to slow down how fast the virus rep...
IL-8)were determined.Results After treatment,the total cure rate of the patients in the treatment group was higher than that in the control group(P0.05),The levels of serum ALT,total bilirubin reduced markedly,however,the levels of serum albumin,and the ratio of A/G,T4 /T8 increased ...
In the 1970s, an unknown virus was suspected for documented cases of transfusion-associated hepatitis, a phenomenon called non-A, non-B hepatitis. In 1989, the infectious transmissible agent was identified and named hepatitis C virus (HCV) and, soon enough, the first diagnostic HCV antibody tes...
We study a mathematical model for hepatitis B consisting of populations of unin- fected liver cells, infected liver cells and free virus. The model includes a non- cytolytic cure process term and a logistic growth term. We show that the model has a disease free equilibrium point and an ende...
HBeAg loss is not a reliable endpoint, given that HBeAg seroreversion or development of HBeAg-negative chronic hepatitis B may occur when treatments are stopped after HBeAg loss. Loss of HBsAg is regarded as the optimal treatment endpoint, or “functional cure.” Unfortunately, with the currently...